M.D. Anderson Cancer Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).

2,692 total trials 549 currently recruiting 1201 completed early-phase tilt top decile by trial count

M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.

M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.

Top-decile sponsor footprint

M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

2,692 total, page 41 of 54

TERMINATED Phase 2

Phase II Neoadjuvant in Inflammatory Breast Cancer

NCT00756470
TERMINATED Phase 1

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

NCT00791271
COMPLETED Phase 2

Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia

NCT00759603
COMPLETED Phase 2

Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide

NCT00800839
COMPLETED Phase 1

Study of Temsirolimus, Topotecan, and Bortezomib

NCT00770731
TERMINATED Phase 2

Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy

NCT00766636
COMPLETED Phase 1

Doxil, Bevacizumab and Temsirolimus Trial

NCT00761644
COMPLETED Phase 2

Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)

NCT00759798
TERMINATED Phase 2

Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer

NCT00745134
COMPLETED

Measuring Non-Enhancing Glioblastoma Progression

NCT00777686
TERMINATED Phase 2

Alemtuzumab + Rituximab Consolidation in CLL

NCT00771602
TERMINATED

Longitudinal Study of Symptoms in Colorectal Cancer

NCT00777192
COMPLETED

Lynne Cohen Consortium Project: Multi-Center Database/Registry

NCT00776958
COMPLETED NA

Validating M.D. Anderson Symptom Inventory (MDASI-GI) in GI Cancer Patients Under Chemotherapy

NCT00849979
TERMINATED NA

Magnetic Resonance Temperature Imaging & Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors

NCT00720837
TERMINATED Phase 2

Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer

NCT00739063
TERMINATED Phase 1

Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes

NCT01029509
COMPLETED Phase 2

Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma

NCT00695786
COMPLETED Phase 2

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

NCT00749892
TERMINATED NA

Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors

NCT00738998
COMPLETED Phase 1

8-Chloro-Adenosine in Chronic Lymphocytic Leukemia

NCT00714103
COMPLETED Phase 1

Phase I Study of TAS-106 in Combo With Carboplatin

NCT00752011
COMPLETED Phase 3

Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)

NCT00750737
COMPLETED NA

Relaxation and Heart Rate Variability

NCT00735618
COMPLETED Phase 3

Education Intervention in Encouraging Health Providers to Talk With Cancer Patients About the Use of Complementary and Alternative Medicine

NCT00608933
COMPLETED Phase 1

Hepatic Arterial Infusion (HAI) of Abraxane

NCT00732836
TERMINATED Phase 2

Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma

NCT00698009
TERMINATED NA

Continuous Glucose Monitoring in Critically Ill

NCT00707434
COMPLETED Phase 4

Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Ablation Therapy

NCT00688038
COMPLETED Phase 2

INCB018424 in Patients With Advanced Hematologic Malignancies

NCT00674479
COMPLETED

Inflammatory Cytokines in Symptom Production in Multiple Myeloma

NCT00688168
COMPLETED

Brain Tumor Patient-Caregiver Congruence, MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT)

NCT00748774
COMPLETED

Perioperative Kinetics of Reactive Hyperemia Using Noninvasive Digital Thermal Monitoring

NCT00683150
COMPLETED Phase 3

Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer

NCT00553059
COMPLETED

Quantitative Analysis of Outcomes in Breast Reconstruction

NCT00677430
TERMINATED Phase 2

Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain

NCT00684242
TERMINATED NA

Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy

NCT00673179
TERMINATED Phase 2

Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia

NCT00623974
COMPLETED

Evaluation of Robot-Assisted Surgery in Gynecologic Oncology

NCT00671827
TERMINATED Phase 1

Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I

NCT00671801
COMPLETED

Attitudes and Beliefs and the Steps of HIV Care

NCT00749840
COMPLETED Phase 3

Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal

NCT00664404
COMPLETED

Palliative Care and Symptom Management for the Pediatric Oncology Patient

NCT00675467
COMPLETED Phase 2

Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

NCT00656617
TERMINATED

Long Term Minor Sibling Donor Well-Being

NCT00667784
TERMINATED Phase 2

Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

NCT00675441
TERMINATED Phase 2

Hysteroscopic Lymphatic Mapping for Endometrial Cancer

NCT00671606
COMPLETED Phase 2

Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma

NCT00654732
COMPLETED Phase 1

Dasatinib in Resectable Malignant Pleural Mesothelioma

NCT00652574
COMPLETED

Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients

NCT00658281
← Previous Page 41 of 54 Next →

Phase Distribution

PhaseTrial count
Phase 1 748
Phase 2 971
Phase 3 96
Phase 4 28

Therapeutic Areas

Hematopoietic and Lymphoid Cell Neoplasm 44
Malignant Solid Neoplasm 42
Breast Cancer 41
Acute Myeloid Leukemia 38
Leukemia 37
Myelodysplastic Syndrome 33
Lymphoma 32
Cancer 31
Recurrent Acute Myeloid Leukemia 25
Lung Cancer 23

What is open in the M.D. Anderson Cancer Center pipeline

549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).

Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).

Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Related

Compare saved trials side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.